FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010793340> ?p ?o ?g. }

• W2010793340 endingPage "109" @default.
• W2010793340 startingPage "104" @default.
• W2010793340 abstract "To evaluate diagnostic and treatment results of malignant intraperitoneal mesothelioma in one setting.12 patients treated for malignant peritoneal mesothelioma from January 2007 to June 2009 in Başkent University Ankara Hospital, Department of Gynaecology and Obstetrics were evaluated. In a retrospective observational study design tumour stage, grade, differentiation, time from first symptoms, pleural involvement, peritoneal cancer index, surgical cytoreduction, chemotherapeutic regimen, number of cycles, disease free survival and overall survival were evaluated. Disease free survival, overall survival, time until first symptoms were researched.The main presenting symptom was abdominal distension. Primary cytoreductive surgery followed by chemotherapy was performed in 9 patients. In 6 patients completeness of cytoreductive score below 2 was achieved. As a first line chemotherapy the most often used was cisplatin in combination with pemetrexed. Themean time from first symptoms until the diagnosis was 1.9 months. Disease free survival of 4.4±1.0 months after completing particular treatment and overall 1-year survival of 85.7 % was observed. No correlations between first symptoms (0.27, p=0.52), time until the diagnosis (-0.29, p=0.44) and overall survival were observed. Similarly, correlations between peritoneal cancer index (0.25, p=0.67), prior surgical score (-.45, p=0.37), completeness of cytoreduction score (0.61, p=0.27) and overall survival were not observed.Because of the low number of patients and different treatment approaches data from a particular patient setting are inconclusive, but from the literature there is evidence that patients with malignant intraperitoneal mesothelioma should undergo optimal cytoreduction and receive a combination of cisplatin and pemetrexed as a first line chemotherapy for intravenous or cisplatin in different chemotherapy regimens using the intraperitoneal administration route, if accessible, with even higher overall survival rates.Tek bir merkezde malign intraperitoneal mezoteliomanın tanı ve tedavi sonuçlarını değerlendirmek.Başkent Üniversitesi Ankara Hastanesi, Kadın Hastalıkları ve Doğum Departmanında Ocak 2007 – Haziran 2009 arasında malign peritoneal mezotelioma için tedavi edilmiş 12 hasta çalışmaya alındı. Retrospektif gözlemsel çalışma dizaynında tümör evresi, derecesi, farklılaşması, ilk semptomlardan beri geçen süre, plevral tutulum, peritoneal kanser indeksi, cerrahi hücre azaltımı, kemoterapötik rejim, tedavi döngülerinin sayısı, hastalıksız sağkalım ve toplam sağkalım değerlendirildi. Hastalıksız sağkalım, toplam sağkalım, ilk semptomlara kadar geçen süre araştırıldı.Başlıca başvuru semptomu karında şişkinlikti. Kemoterapinin izlediği birincil sitoredüktif cerrahi 9 hastada gerçekleştirildi. 6 hastada 2’nin altında sitoredüktif tamlığı skoruna ulaşıldı. İlk seçenek kemoterapi olarak en sık kullanılan pemetreksed ile kombinasyonda sisplatin idi. İlk semptomlardan tanıya kadar geçen ortalama süre 1.9 aydı. Belirli tedavinin tamamlanmasından sonra hastalıksız sağkalım 4.4±1.0 ay ve toplam 1-yıllık sağkalım %85.7 olarak gözlendi. Toplam sağ kalım ile ilk semptomlar (0.27, p=0.52) ve tanıya kadar geçen süre (−0.29, p=0.44) arasında korelasyon gözlenmedi. Benzer şekilde, toplam sağ kalım ile peritoneal kanser indeksi (0.25, p=0.67), önceki cerrahi skoru (−.45, p=0.37), sitoredüksiyon tamlığı skoru (0.61, p=0.27) arasında korelasyon gözlenmedi.Düşük hasta sayısı ve farklı tedavi yaklaşımları nedeniyle bu özel hasta grubundan gelen veriler bir sonuca ulaşmamıştır, fakat literatürde malign intraperitoneal mezoteliomalı hastaların optimal sitoredüksiyon geçirmesi ve ilk seçenek kemoterapi olarak intravenöz sisplatin ve pemetreksed alması veya eğer mümkünse, daha yüksek toplam sağ kalım oranları ile, intraperitoneal uygulama yolunu kullanan farklı kemoterapi rejimlerinde sisplatin alması gerektiğine dair kanıtlar bulunmaktadır." @default.
• W2010793340 created "2016-06-24" @default.
• W2010793340 creator A5010311340 @default.
• W2010793340 creator A5044866817 @default.
• W2010793340 creator A5052680254 @default.
• W2010793340 creator A5055649154 @default.
• W2010793340 creator A5068080107 @default.
• W2010793340 creator A5075497498 @default.
• W2010793340 date "2011-06-01" @default.
• W2010793340 modified "2023-10-09" @default.
• W2010793340 title "Malignant intraperitoneal mesothelioma-Başkent University experience" @default.
• W2010793340 doi "https://doi.org/10.5152/jtgga.2011.24" @default.
• W2010793340 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3939100" @default.
• W2010793340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24591971" @default.
• W2010793340 hasPublicationYear "2011" @default.
• W2010793340 type Work @default.
• W2010793340 sameAs 2010793340 @default.
• W2010793340 citedByCount "1" @default.
• W2010793340 countsByYear W20107933402014 @default.
• W2010793340 crossrefType "journal-article" @default.
• W2010793340 hasAuthorship W2010793340A5010311340 @default.
• W2010793340 hasAuthorship W2010793340A5044866817 @default.
• W2010793340 hasAuthorship W2010793340A5052680254 @default.
• W2010793340 hasAuthorship W2010793340A5055649154 @default.
• W2010793340 hasAuthorship W2010793340A5068080107 @default.
• W2010793340 hasAuthorship W2010793340A5075497498 @default.
• W2010793340 hasBestOaLocation W20107933401 @default.
• W2010793340 hasConcept C126322002 @default.
• W2010793340 hasConcept C141071460 @default.
• W2010793340 hasConcept C142724271 @default.
• W2010793340 hasConcept C143998085 @default.
• W2010793340 hasConcept C146357865 @default.
• W2010793340 hasConcept C151730666 @default.
• W2010793340 hasConcept C2776694085 @default.
• W2010793340 hasConcept C2777240266 @default.
• W2010793340 hasConcept C2777407522 @default.
• W2010793340 hasConcept C2778239845 @default.
• W2010793340 hasConcept C2778995398 @default.
• W2010793340 hasConcept C2781413609 @default.
• W2010793340 hasConcept C71924100 @default.
• W2010793340 hasConcept C86803240 @default.
• W2010793340 hasConceptScore W2010793340C126322002 @default.
• W2010793340 hasConceptScore W2010793340C141071460 @default.
• W2010793340 hasConceptScore W2010793340C142724271 @default.
• W2010793340 hasConceptScore W2010793340C143998085 @default.
• W2010793340 hasConceptScore W2010793340C146357865 @default.
• W2010793340 hasConceptScore W2010793340C151730666 @default.
• W2010793340 hasConceptScore W2010793340C2776694085 @default.
• W2010793340 hasConceptScore W2010793340C2777240266 @default.
• W2010793340 hasConceptScore W2010793340C2777407522 @default.
• W2010793340 hasConceptScore W2010793340C2778239845 @default.
• W2010793340 hasConceptScore W2010793340C2778995398 @default.
• W2010793340 hasConceptScore W2010793340C2781413609 @default.
• W2010793340 hasConceptScore W2010793340C71924100 @default.
• W2010793340 hasConceptScore W2010793340C86803240 @default.
• W2010793340 hasIssue "2" @default.
• W2010793340 hasLocation W20107933401 @default.
• W2010793340 hasLocation W20107933402 @default.
• W2010793340 hasLocation W20107933403 @default.
• W2010793340 hasLocation W20107933404 @default.
• W2010793340 hasOpenAccess W2010793340 @default.
• W2010793340 hasPrimaryLocation W20107933401 @default.
• W2010793340 hasRelatedWork W2007997953 @default.
• W2010793340 hasRelatedWork W2009040992 @default.
• W2010793340 hasRelatedWork W2083305999 @default.
• W2010793340 hasRelatedWork W2142448385 @default.
• W2010793340 hasRelatedWork W2162580433 @default.
• W2010793340 hasRelatedWork W2166686383 @default.
• W2010793340 hasRelatedWork W2603203952 @default.
• W2010793340 hasRelatedWork W2953220268 @default.
• W2010793340 hasRelatedWork W2953636941 @default.
• W2010793340 hasRelatedWork W3042471957 @default.
• W2010793340 hasVolume "12" @default.
• W2010793340 isParatext "false" @default.
• W2010793340 isRetracted "false" @default.
• W2010793340 magId "2010793340" @default.
• W2010793340 workType "article" @default.